Factor VIII Deficiency
9
3
3
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
11.1%
1 terminated out of 9 trials
83.3%
-3.2% vs benchmark
22%
2 trials in Phase 3/4
40%
2 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (9)
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy
A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia A
The European Paediatric Network for Haemophilia Management ( PedNet Registry)
Genetic Factors of the Desmopressin Response in Carriers of Hemophilia A
Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Participants
Pharmacokinetic Characterization of the Hemophilia A Population in Spain Using myPKFiT®
A Study Comparing Factor Level and Inhibitor Titer Testing Results Drawn From Central Venous Lines and Venipuncture
An Institutional Pilot Study to Investigate Physical Activity Patterns in Boys With Hemophilia